Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

What’s New

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

What’s New

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

HTACG Adopts Nine Guidance Documents at 11th Meeting,…

The recent 11th HTA Coordination Group (HTACG) meeting, chaired by Roisín Adams and co-chaired by Marco Marchetti and Niklas Hedberg, resulted in the adoption of nine guidance documentsThe group finalized and approved the "Annual Work Programme for 2025," defining key strategic priorities for the upcoming yearNew guidance documents include procedural instructions for Joint Clinical Assessment (JCA) and Joint Scientific Consultation (JSC) on medicinal products, as well as templates for briefing documents and scoping processes 

EC Issues Procedural Guidance for JCA with 87-Day PICO…

The European Commission has issued “Procedural Guidance for Joint Clinical Assessments (JCA) of Medicinal Products”, outlining the steps for producing JCAs as per the EU Health Technology Assessment Regulation (EU HTAR)In the standard procedure, the Population/Intervention/Comparator/Outcomes (PICO) scoping phase is allocated 87 days, with 21 days specifically designated for the PICO surveyThe document states that there are no clock stops in the JCA procedure, even in cases where the indication changes

Industry Groups Warn of Advisory Shortfall Threatening…

Industry stakeholders are raising urgent concerns over the limited capacity for advice meetings available to pharmaceutical companies planning their clinical trials in 2025With the implementation of the EU Regulation on Health Technology Assessment (HTA) set for January 2025, the first Joint Clinical Assessments (JCA) will be conducted, primarily focusing on new cancer treatments, cell and gene therapiesDespite supporting the goals of the EU regulation, industry leaders point out a significant shortfall. Only five to seven Joint Scientific Consultations are scheduled for 2025, which is far less than the predicted need. With an increasing influx of innovative therapies, more than 50 products are forecasted to require advice

Experts: UK's "Legacy System" Needs Reform to…

During a webinar hosted by the Office of Healthcare Economics (OHE), experts discussed the challenges posed by current pricing models for combination therapies, particularly in cancer treatmentAstellas' Stan Jackson stressed that the industry needs to support bodies like OHE in presenting credible solutions to policymakers. Carole Longson, with experience at NICE & the ABPI, suggested the creation of a "sandbox" to explore possible solutions together and test-drive methodologiesOHE’s report, published in June, proposes a framework for pricing combination therapies using a Combination-Based Differential Pricing (CBDP) model. The framework involves scenario-based classification, flexible pricing models, and value alignment, emphasizing the importance of each component's clinical benefits and cost-effectiveness

NICE Announces Phased Rollout for Mounjaro Following…

In its final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Mounjaro (tirzepatide) for adults with a BMI of ≥35 kg/m² and at least one weight-related comorbidity, to manage overweight and obesity alongside diet and exercise, highlighting its clinical benefits and cost-effectiveness for this populationMounjaro, priced at £122 for four Kwikpens, is not recommended for individuals with a BMI ≥30 kg/m² due to exceeding NICE’s cost-effectiveness thresholdOver the initial three years, around 220,000 people are expected to benefit, and evidence collected during this period will guide the broader rollout to eligible patients

Vertex and Bluebird Bio Agree to Participate in CMS…

Vertex and bluebird bio have agreed to participate in the Centers for Medicare & Medicaid Services' (CMS) new Cell and Gene Therapy (CGT) Access ModelThe CGT Access Model allows CMS to coordinate and administer multi-state outcomes-based agreements (OBAs) with manufacturers for certain cell and gene therapies on behalf of state Medicaid agencies. Under this first iteration of the model, Vertex and bluebird have signed agreements covering their respective gene therapies for Sickle Cell Disease (SCD), Casgevy and LyfgeniaCMS will now move forward with engaging states and U.S. territories that participate in the Medicaid Drug Rebate Program to help them decide whether to participate in the model

HTAR Coordination Group Lines Up 17 Cancer Therapies,…

The Member State Coordination Group on Health Technology Assessment (HTACG) plans to conduct 17 JCAs for new cancer therapies and eight for advanced therapy medicinal products (ATMPs) in 2025 under HTA regulation (EUHTAR)In 2025, 5-7 joint scientific consultations (JSCs) for medicines and 1-3 for medical devices are planned, with submission windows in February and JuneThe JCA and JSC subgroups will convene monthly, while the subgroup for the identification of emerging health technologies (EHT SG) and the subgroup for the development of methodological and procedural guidance (MPG SG) subgroups will meet every two months

China Releases 2024 NRDL, Adds 91 Drugs

China's finalized 2024 National Reimbursement Drug List (NRDL) includes 91 newly added drugs The success rate for negotiations came out to 76% with an average price cut of 63%The new NRDL goes into effect on January 1, 2025. The full list is available in the article 

Abu Dhabi Publishes HTA Guidelines

The Department of Health (DoH) in Abu Dhabi has issued new guidelines for Health Technology Assessment (HTA). These will provide a more structured approach to better manage the adoption and use of emerging health technologies Costly and innovative health technologies, such as gene therapies and specialized biologics, will need to undergo an HTA for coverage and reimbursement decisions. However, generics, biosimilars and low-cost products won't require HTA and will be automatically eligible for reimbursement - please see the article for the full list of inclusions and exclusions Key aspects of the HTA process will include an in-depth clinical evaluation and a budget impact analysis. The clinical evaluation will consider the effectiveness and safety of treatment, measured by clinical trial results and real-world studies. The budget analysis will estimate the potential financial implications of bringing in the new technology, including calculating potential savings achieved from improved health outcomes

BMS Joins Raft of Pharma Companies Suing 340B Program

Bristol Myers Squibb (BMS) is taking legal action against the U.S. Health Resources and Services Administration (HRSA), after the company's proposed rebate model for Eliquis (apixaban) was dismissed by the agencyThe company’s proposed rebate model, set to launch with Eliquis in spring 2025, would require hospitals to pay full price for drugs upfront and submit data confirming 340B eligibility before receiving reimbursementHRSA rejected the plan earlier this month, prompting the lawsuit, in which BMS called the agency’s decision “unlawful three times over.” The company is now seeking court approval to overturn HRSA’s decision and proceed with its rebate model, which it claims is designed to restore compliance and integrity to the program

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!